Navigation Links
Insmed Announces First Quarter 2009 Financial Results

RICHMOND, Va., May 13 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2009.

Recent Company Highlights

  • Follow-on Biologics Program
    • Finalized sale of follow-on biologics (FOB) assets to Merck & Co., Inc., through an affiliate, for gross proceeds of $130 million; and
    • Net of finance and legal fees paid, Insmed has received net proceeds to date of approximately $128 million as a result of this agreement. Taxes due on the sale will be paid by installment during the balance of the year, resulting in total expected net proceeds of approximately $125 million.

    • Continue to expect preliminary Phase 2 data in Myotonic Muscular Dystrophy (MMD) in the second quarter of 2009;
    • The FDA announced that it would allow Insmed to provide access to IPLEX(TM) for investigational use in patients with Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). Insmed will conduct a controlled clinical trial under an Investigational New Drug application;
    • Announced the signing of an agreement with IDIS, a private, UK-based company specializing in the management of medicines on a named patient basis, also known as expanded access programs (EAPs) or named patient programs (NPPs), to manage such programs for IPLEX(TM) worldwide, excluding the U.S. and Italy; and
    • Generated $2.0 million in cost recovery revenue from the IPLEX(TM) EAP for ALS in Italy during the first quarter of 2009.

  • Corporate
    • Regained compliance with NASDAQ's minimum $1.00 per share bid price requirement.

"The year has started off with a litany of positive, value-creating events," said Dr. Geoffrey Allan, Ph.D., President and CEO Insmed. "The transaction with Merck will add about $125 million to our balance sheet and has provided us with significant financial flexibility in terms of how we might go about continuing to grow our business and enhance shareholder value. At the same time, our IPLEX(TM) program continues to move forward on all fronts. We continue to expect preliminary Phase 2 results in MMD before the end of the second quarter. In addition, the ALS EAP is set to expand internationally via our agreement with IDIS, and we are discussing the parameters of a controlled clinical trial in this indication with the FDA in the U.S. As our regaining compliance with NASDAQ's minimum $1.00 per share bid price requirement would indicate, the market is beginning to appreciate our successes, and we look forward to sustaining the momentum we have generated in the first quarter throughout the remainder of the year."

Financial Results for First Quarter Ended March 31, 2009

Total revenues for the first quarter ended March 31, 2009 were $2.4 million, the same as the corresponding period in 2008.

Net income for the first quarter of 2009 increased to $117.8 million, or $0.96 per share, compared with a net loss of $4.9 million, or $0.04 per share, in the first quarter of 2008. This $122.7 million improvement was primarily due to the gain on sale of our FOB assets to Merck which was partially offset by increases in SG&A and R&D expenses due to the recognition of stock compensation expense.

The $2.2 million increase in total expenses was due to a $0.5 million increase in research and development ("R&D expenses") and a $2.1 million increase in selling, general and administrative expenses ("SG&A Expenses"), which was partially offset by the absence of a $0.4 million loss on investments, which was recorded in the first quarter of 2008.

The higher R&D and SG&A Expenses were due largely to the recognition of stock compensation expense for the restricted stock and restricted stock units that vested on March 31, 2009 and the award of bonuses. Interest income for the most recent first quarter of $23,000 was $256,000 lower than the corresponding quarter of 2008 due to a combination of the lower interest rate environment and a lower average cash balance. Interest expense of $242,000 was $112,000 lower than the same quarter in 2008 due to a decrease in the debt discount amortization resulting from the lower average balance of the 2005 convertible notes, which began repayment in March 2008.

As of March 31, 2009, the Company had total cash, cash equivalents and short-term investments on hand of $127.5 million, compared to $2.4 million on hand as of December 31, 2008. The $125.1 million increase in cash, cash equivalents and short-term investments was due to the $127.8 million in net proceeds from the sale of Insmed's FOB assets to Merck, which was minimally offset by $2.1 million utilized to fund operations and $0.6 million for the partial repayment of the Company's 2005 convertible notes.

Conference Call

To participate in today's live 8:30 AM ET conference call, please dial 800-706-7748 (U.S. callers) or 617-614-3473 (international), and provide passcode 81641944. A live webcast of the call will also be available at:

Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning today at 11:30 AM ET at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 62249241.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, [product candidates may fail in the clinic or may not be successfully marketed or manufactured, the FDA may interpret the results of studies differently than us, competing products may be more successful, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD

    Media Contact:
    Irma Gomez-Dib - FD

                                INSMED INCORPORATED
                            Consolidated Balance Sheets
                  (in thousands, except share and per share data)
                                                 March 31,      December 31,
                                                   2009              2008

    Current assets:
      Cash, cash equivalents and short-term
       investments                             $127,540            $2,397
      Accounts receivable, net                      114               122
      Prepaid expenses                               30                74
      Total current assets                      127,684             2,593

    Long-term assets:
      Certificate of deposit                      2,085                 -
      Restricted cash, long-term                      -             2,095
      Deferred financing costs, net                  51                70
      Total long-term assets                      2,136             2,165

    Total assets                               $129,820            $4,758

    Liabilities and stockholders' equity (deficit)
    Current liabilities:
      Accounts payable                           $2,667            $1,277
      Accrued project costs & other                 795               936
      Payroll liabilities                         5,048               453
      Income taxes payable                        2,794                 -
      Restricted stock unit liability                 -               113
      Interest payable                               10                13
      Deferred rent                                 103               168
      Deferred revenue                              232               302

      Convertible debt                            2,211             2,211
      Debt discount                               (476)              (596)
         Net convertible debt                     1,735             1,615

      Total current liabilities                  13,384             4,877

    Long-term liabilities:
      Convertible debt                                -               553
      Debt discount                                   -               (66)
         Net long-term convertible debt               -               487

      Asset retirement obligation                     -             2,217

    Total liabilities                            13,384             7,581

    Stockholders' equity (deficit):
      Common stock; $.01 par value; authorized
       shares 500,000,000; issued and outstanding
       shares, 124,972,146 in 2009 and 122,494,010
       in 2008                                    1,250             1,225
      Additional paid-in capital                343,817           342,378
      Accumulated deficit                      (228,631)         (346,426)
      Net stockholders' equity (deficit)        116,436            (2,823)

    Total liabilities and stockholders'
     equity (deficit)                          $129,820            $4,758

                                 INSMED INCORPORATED
                        Consolidated Statements of Operations
                   (in thousands, except per share data - unaudited)

                                                    Three Months Ended
                                                          March 31,
                                                   2009              2008

    Royalties                                       $28               $25
    Grant revenue                                   272                 -
    Other expanded access program income, net     2,070             2,328
      Total revenues                              2,370             2,353

    Operating expenses:
    Research and development                      5,868             5,368
    Selling, general and administrative           3,449             1,391
    Realized loss on investments                      -               392
      Total expenses                              9,317             7,151

    Operating loss                               (6,947)           (4,798)

    Interest income                                  23               279
    Interest expense                               (242)             (354)
    Gain on sale of asset, net                  127,755                 -
    Income (loss) before taxes                  120,589            (4,873)

    Income tax expense                            2,794                 -

    Net income (loss)                          $117,795           $(4,873)

    Basic net income (loss) per share             $0.96            $(0.04)

    Shares used in computing basic net profit
     (loss) per share                           122,522           121,904

    Diluted net income (loss) per share           $0.96            $(0.04)

    Shares used in computing diluted net
     profit (loss) per share                    122,698           121,904

                                  INSMED INCORPORATED
                         Consolidated Statements of Cash Flows
                               (in thousands - unaudited)

                                                     Three Months Ended
                                                         March 31,
                                                   2009              2008
    Operating activities
    Net income (loss)                          $117,795           $(4,873)
    Adjustments to reconcile net income (loss)
     to net cash used in operating activities:
      Depreciation and amortization                 205               292
      Stock based compensation expense            1,439               133
      Gain on sale of asset, net               (127,755)                -
      Realized loss on investments                    -               392
      Changes in operating assets and liabilities:
        Accounts receivable                           8               (77)
        Other assets                                 44               134
        Accounts payable                          1,390              (100)
        Accrued project costs & other              (141)               12
        Payroll liabilities                       4,595               168
        Income tax liability                      2,794                 -
        Deferred rent                               (65)                -
        Deferred income                             (70)               26
        Restricted stock unit liability            (113)                -
        Asset retirement obligation              (2,217)                -
        Interest payable                             (3)               (3)
    Net cash used in operating activities        (2,094)           (3,896)

    Investing activities
        Cash received from asset sale           127,755                 -
        Decreases in short-term investments           -             5,601
    Net cash provided by investing activities   127,755             5,601

    Financing activities
    Repayment of convertible notes                 (553)             (553)
    Certificate of deposits                          10                 -
    Other                                            25                 -
    Net cash used in financing activities          (518)             (553)

    Increase in cash and cash equivalents       125,143             1,152
    Cash and cash equivalents at beginning
     of period                                    2,397             3,554

    Cash and cash equivalents at end of
     period                                    $127,540            $4,706

    Supplemental information
      Cash paid for interest                        $38               $68

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... maintain healthy metabolism. But unless it is bound to proteins, copper is also ... Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):